ADULT;
AREA UNDER THE CURVE;
ARTICLE;
CONTROLLED STUDY;
DRUG EXCRETION;
DRUG METABOLISM;
ELIMINATION HALF-LIFE;
HUMAN;
HUMAN EXPERIMENT;
MALE;
MAXIMUM PLASMA CONCENTRATION;
NORMAL HUMAN;
RADIOACTIVITY;
TIME TO MAXIMUM PLASMA CONCENTRATION;
URINARY EXCRETION;
ADOLESCENT;
AGONISTS;
CHEMISTRY;
FECES;
METABOLISM;
MIDDLE AGED;
URINE;
Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans
Dalvie D, Chen W, Zhang C, et al. (2008). Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-98.
M3 (R2): Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Available at [last accessed 22 July 2014]
International Conference on Harmonization. (2009) M3(R2): Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Available at: [last accessed 22 July 2014].
Recent advances in the development of selective CB (2) agonists as promising anti-inflammatory agents
Leleu-Chavain N, Body-Malapel M, Spencer J, et al. (2012). Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents. Curr Med Chem 19:3457-74.
Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry
Mailleux P, Vanderhaeghen JJ. (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655-68.
Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent
Odan M, Ishizuka N, Hiramatsu Y, et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg Med Chem Lett 22:2803-6.
Non-clinical evaluation of the metabolism, pharmacokinetics and excretion of S-777469, a new cannabinoid receptor 2 selective agonist
Sekiguchi K, Kanazu T, Takeuchi H, et al. (2013). Non-clinical evaluation of the metabolism, pharmacokinetics and excretion of S-777469, a new cannabinoid receptor 2 selective agonist. Xenobiotica 44:48-58.
US FDA, February 2008 Available at [last accessed 22 July 2014]
US FDA. (2008). United States Food and Drug Administration Guidance for Industry, Safety testing of drug metabolites, February 2008. Available at: RegulatoryInformation/Guidances/ucm065014.htm [last accessed 22 July 2014].
Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites
Wang WW, Khetani SR, Krzyzewski S, et al. (2010). Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 38: 1900-5.
